MACC1 upregulation promotes gastric cancer tumor cell metastasis and predicts a poor prognosis
Xie et al. / J Zhejiang Univ-Sci B (Biomed & Biotechnol) 2016 17(5):361-366
361
Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology)
ISSN 1673-1581 (Print); ISSN 1862-1783 (Online)
www.zju.edu.cn/jzus; www.springerlink.com
E-mail:
MACC1 upregulation promotes gastric cancer tumor cell
metastasis and predicts a poor prognosis*
Qiu-ping XIE§†1, Cheng XIANG§†1, Gang WANG2, Ke-feng LEI3, Yong WANG†‡1
(1Department of General Surgery, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China)
(2Department of Colon Surgery, the Cancer Hospital of Zhejiang Province, Hangzhou 310022, China)
(3Department of General Surgery, Zhejiang Provincial People’s Hospital, Hangzhou 310001, China)
†
E-mail: ; ;
Received Sept. 27, 2015; Revision accepted Dec. 27, 2015; Crosschecked Apr. 15, 2016
Abstract: In various studies, metastasis associated with colon cancer 1 (MACC1) has been frequently reported to be
abnormally highly expressed in human lung cancer, colon cancer, and hepatocellular carcinoma. Our study focuses on
the association of MACC1 expression with gastric cancer (GC). During our experiment, the MACC1 expression was
tested in 105 GC samples using an immunohistochemical (IHC) method. The clinical characteristics and prognosis of
these patients were summarized. During analysis, MACC1 distribution in GC samples with distant metastasis was
higher than that in normal samples and in tumors with no dissemination. Subsequently, a lower 5-year survival rate had
a strong correlation with high MACC1 expression. As a consequence, the present results suggest that MACC1 is more
frequently expressed in a poor prognosis phenotype of GC and acts as a promising prognostic prediction parameter for
GC.
Key words: Gastric cancer, MACC1, Prognosis, Metastasis
http://dx.doi.org/10.1631/jzus.B1500236
CLC number: R735.2
1 Introduction
Gastric cancer (GC) is the fourth most frequently
diagnosed cancer and ranks as the third leading cause
of death from cancer worldwide. In 2011, a global
analysis showed that 989 600 new GC cases and as
many as 738 000 patient deaths occurred in 2008.
Among the population, 70% of cases occur in developing countries, especially in eastern Asia (Jemal
et al., 2011). Over two-thirds of cases present with
advanced or inoperable disease once diagnosed, and
the prognosis is poor (MacDonald, 2006). Despite the
‡
Corresponding author
The two authors contributed equally to this work
*
Project supported by the National Natural Science Foundation of
China (No. 30901445)
ORCID: Qiu-ping XIE, http://orcid.org/0000-0002-4658-5935;
Yong WANG, http://orcid.org/0000-0002-2034-6709
© Zhejiang University and Springer-Verlag Berlin Heidelberg 2016
§
wide usage of advanced surgical techniques (Lee
et al., 2008) and chemotherapy (Sun et al., 2009), the
overall recovery rate for patients continues to remain
poor (Morabito et al., 2009). GC pathogenesis is a
complex, multistage, and heritage-related process. So
far, the researches associated with GC mechanisms
are far from understood. Various pathological and
epidemiological studies have provided evidence that
genetic factors play a crucial role in gastric carcinogenesis (González et al., 2002; Hamajima et al., 2006).
As a feature of malignant tumors, metastasis is
mainly related to GC prognosis and the major factors
of GC recurrence. Furthermore, lymph node and peritoneal metastasis are highly associated with a poor
GC prognosis. We are very interested in the undiscovered molecular changes in distant metastasis tumors.
In colon cancer, metastasis associated with colon
cancer 1 (MACC1) gene was first identified to be
differentially expressed by a gene expression contrast
362
Xie et al. / J Zhejiang Univ-Sci B (Biomed & Biotechnol) 2016 17(5):361-366
search by comparing normal colon mucosa, primarystage tumors, and metastases lesions (Stein et al.,
2009). It induces tumor proliferation, metastasis, and
invasion in in vitro colon epithelium cancer cell culture, as well as in colon cancer patients (Arlt and Stein,
2009). Besides this, MACC1 acts as the main regulator factor of the HGF/Met pathway, and influences
cell activity through downstream MAPK upregulation (Stein et al., 2009). In previous studies, high
MACC1 expression was found to be present in various cancer tissues including colon cancer (Shirahata
et al., 2010a), hepatocarcinoma (Shirahata et al.,
2011), and lung adenocarcinoma (Chundong et al.,
2011; Shimokawa et al., 2011).
Accumulating evidence suggests that the high
expression of MACC1 has been proved to be associated with increased metastasis risk and poorer patient
survival in various types of cancers including bladder
urothelial carcinoma (Xu et al., 2015), cervical cancer
(Zhou et al., 2015), and colorectal cancer (Weidle
et al., 2015). Recently, upregulation of MACC1 expression was reported in GC (Shirahata et al., 2010b).
MACC1 was reported to play a key role in GC metastasis (Wang et al., 2013), epithelial-mesenchyal
transition (EMT) phenomena (Huang et al., 2015),
and angiogenesis (Sun et al., 2015). Until now, the
role of MACC1 in GC has still remained controversial
(Ge et al., 2011). During our work, we investigated
MACC1 expression in surgical specimens from 105
GC patients, and we identified the correlation between MACC1 expression and various clinic pathological parameters.
2 Materials and methods
2.1 Patients and tissue samples
GC tissue was obtained from 105 patients who
were pathologically proven and underwent surgical
operation between January 2004 and December 2006
in our hospital. None of the 105 patients had received
neoadjuvant before operation. The tissue samples
were formalin-fixed and paraffin-embedded following surgical removal, then were cut into thick sections
(4 µm) and mounted onto glass slides for further
protein expression analysis. The clinical characteristics of these patients, such as gender, age, tumor location, differentiation, and tumor-node-metastasis
(TNM) stage, are summarized in Table 1. Follow-up
by consultation of the case documents or by telephone
was performed until death or June 2011, whichever
came first. The clinical stage of the tumors was determined according to the TNM classification of the
International Union Against Cancer (2009) (Edge and
Compton, 2010). Thirty normal tissue specimens
from gastritis patients without malignancy undergoing endoscopic biopsy were collected as blank controls. The present study was approved by the Ethical
Committee of the Second Affiliated Hospital of
Zhejiang University and the Zhejiang Provincial
People’s Hospital, China.
2.2 Immunohistochemical staining of MACC1
Immunohistochemical (IHC) examination of
MACC1 was performed using rabbit anti-MACC1
polyclonal antibody (Abcam, Hong Kong, China) on
the specimens described previously. Tissue sections
were first incubated at 60 °C for 2 h, followed by
deparaffinizing them in xylene; then they were rehydrated in a list of graded alcoho (...truncated)